Stone Pharmaceutical Group: SYH2085 tablets approved for clinical trials in China.

Shiyao Group Announcement: The SYH2085 tablet developed by the group has been approved by the National Medical Products Administration of the People's Republic of China for clinical trials in China. This product is a chemically innovative drug independently developed by the group, which is a new oral small molecule candidate drug that can inhibit the RNA-dependent RNA polymerase acidic protein endonuclease activity of the influenza virus. The approved clinical indication for this time is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above.